Thermo Fisher Scientific announced the expansion of its oral solid dose footprint with investments in its manufacturing sites in Cincinnati, Ohio and Bend, Oregon, enabling pharma customers to keep up with growing industry demand.
Together, these expansions will enable R&D, manufacturing and testing of OSD drug formulations — doubling the Bend site’s existing footprint and continuing a multi-year investment plan in Cincinnati — to bolster capabilities across the company’s global CDMO and CRO network.
According to Thermo Fisher Scientific, the company has invested a total of $22 million since 2021 in the Cincinnati and Bend sites.
To meet the increasing demand for small molecule OSD solutions, the Cincinnati facility upgrade will add dedicated flexible R&D space, supporting pre-clinical early development of OSD formulations through rapid project initiation and the use of next-gen technologies for data-informed decision-making. The Bend expansion is focused on R&D manufacturing and testing, including bench and pilot scale spray drying, hot-melt extrusion and dry granulation. These additions to the site bolster capabilities at the company’s center of excellence for early development and advanced drug delivery, including solubility and bioavailability enhancement solutions and digital modeling.
The expansions in Cincinnati and Bend build on the company's continued investment in small molecule OSD solutions, including development and manufacturing services in Bourgoin, France; Manatí, Puerto Rico; Toronto, Canada; Whitby, Canada; and continuous manufacturing in Greenville, NC. The company has led OSD development by supporting over 125 new drug approvals for clients during the last decade (2011–2023), in addition to producing billions of tablets and capsules annually.